Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0001484

Medroxyprogesterone 17-acetate

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Medroxyprogesterone 17-acetate, 17α-Acetoxy-6α-methylprogesterone, 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate, 6α-Methyl-17α-acetoxyprogesterone, 6α-Methyl-17α-hydroxyprogesterone acetate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C24H34O4
Número de CAS:
71-58-9
Peso molecular:
386.52
Beilstein:
2066112
Número MDL:
MFCD00010483
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329831450
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

medroxyprogesterone

fabricante / nombre comercial

EDQM

mp

206-207 °C (lit.)

aplicaciones

pharmaceutical (small molecule)

formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O

InChI

1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

Clave InChI

PSGAAPLEWMOORI-PEINSRQWSA-N

Información sobre el gen

human ... PGR(5241)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Medroxyprogesterone acetate for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

1378001

Medroxyprogesterone 17-acetate, United States Pharmacopeia (USP) Reference Standard

1378012

Medroxyprogesterone acetate Related Compound A, United States Pharmacopeia (USP) Reference Standard

Y0000598

Medroxyprogesterone 17-acetate, European Pharmacopoeia (EP) Reference Standard

M0250000

Medroxyprogesterone 17-acetate, European Pharmacopoeia (EP) Reference Standard

PHR1589

Medroxyprogesterone 17-acetate, Pharmaceutical Secondary Standard; Certified Reference Material

1378023

Medroxyprogesterone, United States Pharmacopeia (USP) Reference Standard

BP221

Medroxyprogesterone 17-acetate, British Pharmacopoeia (BP) Reference Standard

Pictogramas

Health hazard
GHS08

Palabra de señalización

Warning

Frases de peligro

H351,H413

Clasificaciones de peligro

Aquatic Chronic 4 - Carc. 2

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Edith R Guilbert et al.
Contraception, 79(3), 167-177 (2009-02-03)
In the fall of 2007, the controversy about the contraceptive use of depot-medroxyprogesterone acetate (DMPA) and its potential impact on skeletal health reached the media in the province of Quebec, Canada, thereby becoming a matter of concern for the lay
Carolyn Westhoff
Contraception, 68(2), 75-87 (2003-09-05)
Depot-medroxyprogesterone acetate (Depo-Provera(R)) is a highly effective, nondaily hormonal contraceptive option that has been available in the United States for a decade, and worldwide for 40 years. Benefits and risks of hormonal therapy are often under scrutiny; however, long-term clinical
J Mitsushita et al.
Gynecologic oncology, 79(1), 129-132 (2000-09-28)
Successful pregnancies after conservative progestin treatment to young women with endometrial carcinoma have recently been reported. However, it is not known for certain whether the lesion is completely eradicated in such patients. We present a case of residual endometrial carcinoma
Summer Day et al.
Journal of acquired immune deficiency syndromes (1999), 66(4), 452-456 (2014-05-07)
Depot medroxyprogesterone acetate (DMPA) use among HIV-1-infected women may increase transmission by increasing plasma and genital HIV-1 RNA shedding. We investigated associations between DMPA use and HIV-1 RNA in plasma and cervical secretions. One hundred two women initiated antiretroviral therapy
Andrea N Simpson et al.
Gynecologic oncology, 133(2), 229-233 (2014-02-25)
Oral progestin is an alternative to hysterectomy for women with complex atypical hyperplasia (CAH) or grade one endometrial cancer (G1EC) who wish fertility preservation. We evaluated treatment efficacy and fertility outcomes in this population. Women <45 y treated with oral
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico